AMRC vs CBZ

The company exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant fundamental deterioration. Despite recent earnings surprises and positive short-term growth momentum, high leverage (Debt/Equity of 2.25), low profitability margins, and a lack of Altman Z-Score due to potential distress risk raise serious concerns. The stock trades well above its Graham Number of $23.05 and intrinsic value of $19.06, implying overvaluation relative to defensive and growth-based metrics. Bearish insider activity and inconsistent earnings performance further undermine confidence in a sustainable turnaround.

CBZ presents a complex profile with a stable but mediocre Piotroski F-Score of 4/9 and a missing Altman Z-Score, indicating a lack of strong financial momentum. While the stock appears undervalued based on the Graham Number ($36.84) and a Price-to-Book ratio of 0.93, it trades significantly above its growth-based intrinsic value ($12.81). Strong revenue growth (17.9%) is currently offset by a concerning negative operating margin (-7.37%) and a severe 1-year price decline of 53.8%. The disconnect between analyst 'Buy' ratings and bearish insider activity suggests a high-risk value play.